Abstract
Introduction
Hearing loss is the most common sensory deficit. In children, its prevalence is approximately 1 in 1,000 population. 1 Sensorineural hearing loss (SNHL) is often caused by impairment of hair cell or auditory neurons and is often irreversible. Many genetic (monogenic, polygenic) and environmental (infections, premature birth, noise, ototoxic drugs) factors have been known to cause this etiologically heterogeneous condition. 2, 3 Approximately 50 to 60% of all cases of hearing loss have been attributed to inherited or genetic factors. 2, 4, 5 Among a plethora of deafness gene mutations, mutations of GJB2, SLC26A4, GJB3, and MT-RNR1 are the most common, 6 accounting for more than 40% of cases in patients with hereditary hearing loss. 7, 8 GJB2 (connexin 26 gene) is the most commonly implicated gene in SNHL. In China, approximately 26% of patients with hearing loss have been reported to have at least one mutated allele in GJB2. 9 Among all mutations in GJB2, the most common in Asian populations is c.235delC. 10 Mutations in GJB3, the first deafness gene cloned in the Chinese population, 11 have been associated with progressive hearing loss.
It has been reported that a sex difference exists in patients with a heterozygous c.538C>T or c.547G>A mutation. The phenotype of c.538C>T and c.547G>A mutations of GJB3 was variable, with men presenting with progressive or late-onset profound deafness, while women's was either subclinical or not detectable. 12, 13 Mutations in SLC26A4 are a major cause of an enlarged vestibular aqueduct (EVA), and c.919-2A>G is the most common mutation. 14, 15 Mutations in the mitochondrial 12S rRNA gene (MT-RNR1) often lead to severe or profound SNHL when carriers are exposed to aminoglycoside antibiotics.
Many recent studies have focused on newborn genetic screening for the presence of 20 common mutations in the four deafness-related genes: GJB2, SLC26A4, GJB3, and MT-RNR1. However, the prevalence of the 20 common mutations in patients with various degrees of hearing loss has been less often reported. Moreover, phenotype-genotype correlation after newborn genetic screening in deaf children needs to be better elucidated.
In this article, we describe our study of 20 common hot-spot mutations in deaf children; we also evaluate the phenotype-genotype correlation.
Patients and methods
From June 2013 through May 2014, 103 children were diagnosed with hearing loss at two rehabilitation centers for deaf children and in the outpatient clinic of Shaoxing Maternal and Child Health Care Hospital in the city of Shaoxing in Zhejiang province, China. This group was made up of 56 boys and 47 girls, aged 5 months to 9 years (mean: 4.1 yr).
All patients underwent a complete examination and audiologic assessment, and conductive hearing loss was excluded. Genetic screening was carried out in all patients. Magnetic resonance imaging (MRI) or computed tomography (CT) was obtained to detect radiologic abnormalities. A diagnosis of aplasia of the auditory nerve was based on the results of high-resolution nuclear MRI and audiometric analysis, such as pure-tone audiometry and measurements of distortion-product otoacoustic emissions.
Of the 103 children, none had a mild hearing loss, 19 (18.4%) had a moderate loss, 26 (25.2%) a severe loss, and 58 (56.3%) a profound loss. Eleven children (10.7%) had some family history of deafness. With respect to clinical malformations, 13 patients (12.6%) had an EVA, 3 (2.9%) had aplasia of the auditory nerve, 2 (1.9%) had an inner ear malformation, 1 (1.0%) had cochlear hair cell degeneration, and 1 had cerebral atrophy (table 1) .
Audiologic assessments. For patients younger than 5 years, auditory brainstem response (ABR) testing was used to obtain the most accurate findings; for patients aged 5 years and older, pure-tone audiometry was carried out in addition to ABR testing. A stimulus intensity of 30 dB nHL was used in the initial ABR screening. Replicable wave-V thresholds of 30 dB nHL or less indicated normal hearing. ABR wave-V thresholds of more than 30 dB nHL indicated various degrees of hearing loss, including mild (31 to 50 dB nHL), moderate (51 to 70), severe (71 to 90), and profound (≥91) hearing loss. Conductive deafness was excluded using acoustic immittance measurement.
Genetic analysis. The genetic screening looked for 20 common hot-spot mutations in four nonsyndromic hearing-loss-related genes: GJB2, SLC26A4, GJB3, and MT-RNR1. The mutations were detected by multiple-PCR-based MALDI-TOF MS assay as previously described. 12 Briefly, after DNA was extracted from blood samples, each mutation allele that had allele-specific extending probes with different molecular weight in the reaction could be separated by MALDI-TOF MS. All the reactions could be carried out in a single well or tube. Confirmation of validation was obtained with both wild and mutant types by Sanger sequencing.
Ethical considerations. The study was performed with the approval of the Ethics Committee at Shaoxing Maternal and Child Health Care Hospital. Informed consent was obtained from guardians on behalf of all children enrolled.
Results

Frequency of 20 hot-spot mutations.
At least one mutated allele was detected in 48 patients (46.6%); 35 patients (34.0%) had a GJB2 mutation and 13 (12.6%) had an SLC26A4 mutation. We did not detect any mutations in the GJB3 and MT-RNR1 genes. Pathogenic mutations were detected in 30 patients (29.1%), including 16 patients with homozygote for GJB2 c.235delC, 8 with compound heterozygote for GJB2, 4 with homozygote for SLC26A4 c.919-2A>G, and 2 with compound heterozygote for SLC26A4 (table 2) .
For determining the allele frequencies for the 20 deafness-related mutations, patients with two different mutation alleles were counted twice because each allele was counted individually. GJB2 c.235delC and SLC26A4 c.919-2A>G were the two most common mutations, with allele frequencies of 23.8% and 6.8% of all alleles (N = 206), respectively (table 3, figure) .
Analysis of phenotype-genotype correlation. For the 11 patients with mutated alleles who had a family history of deafness, we compiled detailed information 12, 16 Our study confirmed that; the GJB2 c.235delC and SLC26A4 c.919-2A>G mutations were the two most common, with an allele frequency of 23.8% and 6.8% in all alleles (n = 206), respectively.
We also found that three deletion frameshift mutations of GJB2 (c.235delC, c.176_191del16, and c.299_300delAT) have higher frequencies than do other detected mutations. Snoeckx et al classified these three mutant alleles as truncating mutations. 18 They reported that truncating mutations of GJB2 were associated with a greater degree of hearing loss than were non-truncating mutations. In our study, patients who were homozygous and compound heterozygous for GJB2 (c.235delC/c.235delC, c.235delC/c.176_191del16, and c.176_191del16/c.299_300delAT) all had homozygous truncating mutations. Most patients with homozygous truncating mutations experienced a great degree of hearing loss. We detected no nontruncating mutant alleles in our study. This might suggest that the non-truncating mutations are less pathogenic.
on their age at onset, genotype, ABR findings in both ears, and radiologic malformations (table 4). Only 1 of these patients was homozygous for SLC26A4 c.919-2A>G, and 2 were compound heterozygous. The rest were all heterozygous for only one mutated allele. Three patients were unable to pass a newborn hearing screen. The oldest age at diagnosis was 30 months.
Of the 13 patients with EVA, all had at least one mutant allele in SLC26A4 (table 5) . Only 1 of the 3 patients with aplasia of the auditory nerve was homozygous f or GJB2 c.235delC. Genetic mutations were not detected in the remaining 6 patients with clinical malformations.
Discussion
Our study revealed that at least one mutant allele was detected in 48 (46.6%) of the 103 deaf children, including 35 (34.0%) with a GJB2 mutation and 13 (12.6%) with an SLC26A4 mutation. We did not find any mutations in GJB3 and MT-RNR1. The frequency of the common deafness genes in our study was slightly higher than what others have reported. 7, 16, 17 This might be attributable to regional differences or to the number of mutant alleles se- It is interesting that the frequency of the other mutant alleles in GJB2 (except c.235delC) varied significantly, both in newborns and children, especially c.299_300delAT, c.167_191del16, and c.538C>T. Zhang et al reported that in newborns, the frequency of c.299_300delAT was 0.53%, while the frequency of c.167_191del16 was 0.12%. 12 However, in our study, we found that the allele frequency of c.167_191del16 (3.4%) was obviously higher than that of c.299_300delAT (1.5%). Qu et al reported that the frequencies of these two alleles were similar. 16 By comparing our finding with those of Qu et al, we believe that the difference might be attributable to the frequency of compound heterozygotes for both alleles.
The frequency of c.538C>T has been reported to be higher than that of c.176_191del16. 12 No c.538C>T was detected in our study. This may suggest that a regional difference exists or that c.538C>T is less pathogenic than c.176_191del16. However, it should be noted that the relatively small sample size and sample randomness of our local study might be another explanation for this observation. Future studies that include more patients should be carried out to provide a basis for more solid modifications for newborn gene screening in different geographic regions. Mutations of SLC26A4 are the second most common cause of hereditary hearing loss worldwide. The spectrum of common SLC26A4 mutations varies among different races and ethnicities; c.919-2A>G is more common than c.2168A>G in Chinese and Northern European populations, 17, 19 while c.2168A>G is more prevalent than c.919-2A>G in the Japanese population. 20 In our study, we detected SLC26A4 mutations in 13 patients (12.6%); the most prevalent mutation was c.919-2A>G. Three of 4 patients homozygous for c.919-2A>G had progressive hearing loss. In addition, the SLC26A4 gene encoding the Pendrin protein can cause hearing loss in patients with an EVA.21,22 In our study, all 13 patients with a SLC26A4 mutation had an EVA.
Mutations of GJB3 c.547G>A and c.538C>T were first associated with autosomal dominant hearing impairment in two Chinese families in a report by Xia et al in 1998. 11 Since then, c.547G>A and c.538C>T have been widely detected in newborn hearing genetic screening programs and in genetic analyses of hearing loss patients in China. A sex difference exists in the phenotype of c.538C>T and c.547G>A mutations in GJB3, as men presented with progressive or late-onset hearing loss, while the women's was either subclinical or not detectable. 12, 13 Zhang et al reported a carrier frequency of 0.5% in newborns in Tianjin, China, for GJB3, with no infants experiencing hearing loss. 12 They suggested that special attention be paid to hearing development in these children. Considering the characteristics of late-onset GJB3 mutations, screening for GJB3 mutations was still included in our study. We found no GJB3 mutations. The reason for this might be that the GJB3 mutations carrier was normal at birth or it might have been attributable to the sex difference in GJB3 carriers. 13 Mutations in mitochondrial gene MT-RNR1 are associated with aminoglycoside ototoxicity, and carriers should be kept away from aminoglycosides throughout their lifetimes to avoid drug-induced deafness. In our study, mutations in MT-RNR1 were not detected. This may be a reflection of the benefit of nationwide newborn genetic screening in China, which has led to cautious drug prescribing for GJB3 carriers for the purpose of avoiding drug-induced hearing loss.
In our previous genetic study in children, which involved 4,025 newborns in Shaoxing, we detected MT-RNR1 mutations in 5 children (0.12%), suggesting that GJB3 mutations do exist in our area. 23 In conclusion, our study found that almost half of the children with SNHL carried a common deafness-related mutation, and nearly one-third carried a pathogenic mutation. We also found that the SLC26A4 mutations are correlated strongly with EVA. However, our study was limited by the relatively small number of patients. We detected the mutations in only 103 children with hearing loss, and only 48 of them were found to have least one mutated allele. This limits the generalizability of our findings. Larger studies of patients with a wider age range need to be conducted.
